JLE

Hépato-Gastro & Oncologie Digestive

MENU

Cancer du pancréas métastatique : quelles thérapies au-delà de la chimiothérapie cytotoxique ? Volume 30, issue 7, September 2023

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 Université Paris Saclay, Université Versailles Saint-Quentin, Institut Curie, Département d’Oncologie Médicale, 35 rue Dailly, 92210 Saint-Cloud
2 Institut Curie, CNRS, UMR144, équipe Oncologie Moléculaire, Paris
3 Université Paris Saclay, Université Versailles Saint-Quentin, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Ambroise-Paré, Département de Chirurgie Oncologique, EA4340-BECCOH, Boulogne-Billancourt
* Correspondance : C. Neuzillet

The management of pancreatic ductal adenocarcinoma (PDAC) is guided by the extent of the disease and the patient’s general condition and relies primarily on chemotherapy in the metastatic setting. Recent data have enabled us to better characterize PDAC and their microenvironment at both cellular and molecular levels, and to better understand patients suffering from PDAC as a whole. These data are leading to better stratification of patients and personalization of treatments, as well as the development of new strategies for bio-guided choice of chemotherapy, immunotherapies, targeted therapies and supportive care. This mini-review provides an update on the development of new therapies for metastatic PDAC beyond cytotoxic chemotherapy, and presents current challenges to this development.